Otsuka Holdings Co.,Ltd.: U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-month, Ready-to-Use, LAI to Treat Schizophrenia and Bipolar I Disorder in Adults

Source :: Plus Company Updates. September 14, 2022
Publication Year :: 2022
Abstract: Tokyo: Otsuka Holdings Co.,Ltd. has issued the following news release: Otsuka America Pharmaceutical, Inc., (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the U.S. Food and Drug Administration (FDA) acceptance of [...]

Subjects :: United States. Food and Drug Administration
Otsuka Holdings Company Ltd.
H. Lundbeck A/S
Bipolar disorder -- Drug therapy
Aripiprazole
Schizophrenia -- Drug therapy
Adults
General interest
News, opinion and commentary

Tools